검색어 : 통합검색[Kaufman Charlie]
총 73건 중 73건 출력
, 7/8 페이지
-
61
- Antitumor activity of motesanib alone and in combination with cisplatin or docetaxel in multiple human non–small-cell lung cancer xenograft models
- Coxon, Angela; Ziegler, Beth; Kaufman, Stephen; Xu, Man; Wang, Hongyu; Weishuhn, Dawn; Schmidt, Joanna; Sweet, Heather; Starnes, Charlie; Saffran, Douglas; Polverino, Anthony; Department of Oncology Research, Amgen Inc, One Amgen Centre Drive, Thousand Oaks, CA 91320, USA; Department of Oncology Research, Amgen Inc, One Amgen Centre Drive, Thousand Oaks, CA 91320, USA; Department of Pathology, Amgen Inc, One Amgen Centre Drive, Thousand Oaks, CA, 91320, USA; Department of Oncology Research, Amgen Inc, 360 Binney Street, Cambridge, MA, 02142, USA; Department of Protein Sciences, Amgen British Columbia, 7990 Enterprise St, Burnaby, BC, V5A 1V7, Canada; Department of Protein Sciences, Amgen British Columbia, 7990 Enterprise St, Burnaby, BC, V5A 1V7, Canada; Department of Oncology Research, Amgen Inc, One Amgen Centre Drive, Thousand Oaks, CA 91320, USA; Department of Protein Sciences, Amgen British Columbia, 7990 Enterprise St, Burnaby, BC, V5A 1V7, Canada; Department of Oncology Research, Amgen Inc, One Amgen Centre Drive, Thousand Oaks, CA 91320, USA; Department of Oncology Research, Amgen Inc, 360 Binney Street, Cambridge, MA, 02142, USA; Departmen; (Molecular cancer, v.11, 2012, pp.70-70)
-
62
- “With Every Step, We Grow Stronger”: The Cardiometabolic Benefits of an Indigenous-Led and Community-Based Healthy Lifestyle Intervention
- Lai, Henry P.H.; Miles, Rosalin M.; Bredin, Shannon S.D.; Kaufman, Kai L.; Chua, Charlie Z.Y.; Hare, Jan; Norman, Moss E.; Rhodes, Ryan E.; Oh, Paul; Warburton, Darren E.R.; Cardiovascular Physiology and Rehabilitation Laboratory, University of British Columbia, Vancouver, BC V6T 1Z4, Canada; henry.lai@ubc.ca (H.P.H.L.); kai.kaufman@ubc.ca (K.L.K.); charliezongyu@alumni.ubc.ca (C.Z.Y.C.); Indigenous Studies in Kinesiology, Faculty of Education, University of British Columbia, Vancouver, BC V6T 1Z4, Canada; rosalin.miles@ubc.ca (R.M.M.); shannon.bredin@ubc.ca (S.S.D.B.); jan.hare@ubc.ca (J.H.); moss.norman@ubc.ca (M.E.N.); Indigenous Studies in Kinesiology, Faculty of Education, University of British Columbia, Vancouver, BC V6T 1Z4, Canada; rosalin.miles@ubc.ca (R.M.M.); shannon.bredin@ubc.ca (S.S.D.B.); jan.hare@ubc.ca (J.H.); moss.norman@ubc.ca (M.E.N.); Cardiovascular Physiology and Rehabilitation Laboratory, University of British Columbia, Vancouver, BC V6T 1Z4, Canada; henry.lai@ubc.ca (H.P.H.L.); kai.kaufman@ubc.ca (K.L.K.); charliezongyu@alumni.ubc.ca (C.Z.Y.C.); Cardiovascular Physiology and Rehabilitation Laboratory, University of British Colum; (Journal of clinical medicine, v.8, 2019, pp.422)
-
63
- Long-term exposure to air pollution, greenness and temperature and survival after a nonfatal myocardial infarction
- Klompmaker, Jochem O.; Laden, Francine; Dominici, Francesca; James, Peter; Josey, Kevin P.; Kaufman, Joel; Nethery, Rachel C.; Rimm, Eric B.; Roscoe, Charlie; Wilt, Grete; Yanosky, Jeff D.; Zanobetti, Antonella; Hart, Jaime E.; ; (Environmental pollution, v.355, 2024, pp.124236)
-
64
- Phase II, Open-Label, Randomized, Multicenter Study Comparing the Efficacy and Safety of Olaparib, a Poly (ADP-Ribose) Polymerase Inhibitor, and Pegylated Liposomal Doxorubicin in Patients With <i>BRCA1</i> or <i>BRCA2</i> Mutations and Recurrent Ovarian Cancer
- Kaye, Stan B.; Lubinski, Jan; Matulonis, Ursula; Ang, Joo Ern; Gourley, Charlie; Karlan, Beth Y.; Amnon, Amit; Bell-McGuinn, Katherine M.; Chen, Lee-May; Friedlander, Michael; Safra, Tamar; Vergote, Ignace; Wickens, Mark; Lowe, Elizabeth S.; Carmichael, James; Kaufman, Bella; Author affiliations appear at the end of this article.; Author affiliations appear at the end of this article.; Author affiliations appear at the end of this article.; Author affiliations appear at the end of this article.; Author affiliations appear at the end of this article.; Author affiliations appear at the end of this article.; Author affiliations appear at the end of this article.; Author affiliations appear at the end of this article.; Author affiliations appear at the end of this article.; Author affiliations appear at the end of this article.; Author affiliations appear at the end of this article.; Author affiliations appear at the end of this article.; Author affiliations appear at the end of this article.; Author affiliations appear at the end of this article.; Author affiliations appear at the end of this article.; Author affiliations appear at the end of this article.; (Journal of clinical oncology : official journal of the American Society of Clinical Oncology, v.30, 2012, pp.372-379)
-
65
- AMG 706, an Oral, Multikinase Inhibitor that Selectively Targets Vascular Endothelial Growth Factor, Platelet-Derived Growth Factor, and Kit Receptors, Potently Inhibits Angiogenesis and Induces Regression in Tumor Xenografts
- Polverino, Anthony; Coxon, Angela; Starnes, Charlie; Diaz, Zobedia; DeMelfi, Thomas; Wang, Ling; Bready, James; Estrada, Juan; Cattley, Russell; Kaufman, Stephen; Chen, Danlin; Gan, Yongmei; Kumar, Gondi; Meyer, James; Neervannan, Sesha; Alva, Gonzalo; Talvenheimo, Jane; Montestruque, Silvia; Tasker, Andrew; Patel, Vinod; Radinsky, Robert; Kendall, Richard; ; (Cancer research : the official organ of the American Association for Cancer Research, Inc, v.66, 2006, pp.8715-8721)
-
66
- Characterization of ovarian cancer long-term responders on olaparib.
- Lheureux, Stephanie; Ledermann, Jonathan A.; Kaye, Stanley B.; Gourley, Charlie; Friedlander, Michael; Bowtell, David; De Greve, Jacques; deFazio, Anna; Shapira-Frommer, Ronnie; De Bono, Johann Sebastian; Audeh, M. William; Kohn, Elise C.; Alsop, Kathryn; Scott, Clare L.; Matulonis, Ursula; Kaufman, Bella; Burger, Brent; Robertson, Jane D; Ho, Tony; Oza, Amit M.; Princess Margaret Cancer Centre, Toronto, ON, Canada; University College London Cancer Institute, London, United Kingdom; Drug Development Unit at The Institute of Cancer Research and The Royal Marsden NHS Foundation Trust, London, UK, London, United Kingdom; Edinburgh Cancer Research UK Centre, Edinburgh, United Kingdom; Prince of Wales Hospital, Sydney, Australia; Peter MacCallum Cancer Centre, Melbourne, Australia; Familial Cancer Clinic and Medical Oncology, University Hospital Brussels, UZ Brussel, Brussels, Belgium; Westmead Institute for Cancer Research, University of Sydney at Westmead Millennium Institute, Sydney, Australia; Ella Institute for Research and Treatment of Melanoma, Sheba Medical Center, Affiliated to Sackler Faculty of Medicine Tel Aviv University, Tel Hashomer, Israel; The Royal Marsden NHS Foundation Trust, Surrey, United Kingdom; Samuel Oschin Comprehensive Cancer Institute, Cedars-Sinai Medical Center, Los Angeles, CA; National Cancer Institute, Na; (Journal of clinical oncology : official journal of the American Society of Clinical Oncology, v.32, 2014, pp.5534-5534)
-
67
- What clinical factors influence advanced <i>BRCA1/2</i> mutant ovarian cancer patient (BMOC pt) outcomes to poly(ADP-ribose) polymerase inhibitor (PARPi) treatment?
- Rafii, Saeed; Gourley, Charlie; Ang, Joo Ern; Kumar, Rajiv; Geuna, Elena; Rye, Tzyvia; Ashcroft, Linda; Powell, Bethan; Shapira-Frommer, Ronnie; Friedlander, Michael; Chen, Lee-may; Matulonis, Ursula; Kaufman, Bella; De Greve, Jacques; Oza, Amit M.; Banerjee, Susana N.; Gore, Martin Eric; Molife, L Rhoda; Kaye, Stanley B.; Yap, Timothy Anthony; The Institute of Cancer Research and The Royal Marsden NHS Foundation Trust, Sutton, United Kingdom; University of Edinburgh Cancer Research UK Centre, Edinburgh, United Kingdom; Royal Marsden Hospital, Sutton Surrey, United Kingdom; The Royal Marsden Hospital, London, United Kingdom; The Institute Of Cancer Research and Royal Marsden, Osasco, Italy; University of Edinburgh Clinical Trials Unit, Edinburgh, United Kingdom; Clinical Trials Unit, The Christie NHS Foundation Trust, Manchester, United Kingdom; UC San Francisco, San Francisco, CA; Sheba Medical Center, Ramat Gan, Israel; Prince of Wales Cancer Centre, Randwick, Australia; UC San Francisco, San Francisco, CA; Dana-Farber Cancer Inst, Boston, MA; Sheba Medical Center; affiliated with Sackler Faculty of Medicine (Tel Aviv Univ), Ramat Gan, Israel; Oncologisch Centrum UZBrussel, Brussels, Belgium; Princess Margaret Cancer Centre, University Health Network, Toronto, ON, Canada; Royal Marsden Hospital, London, Unite; (Journal of clinical oncology : official journal of the American Society of Clinical Oncology, v.33, 2015, pp.5546-5546)
-
68
- Use of chemotherapy (CT) in <i>BRCA1/2</i>-deficient ovarian cancer (BDOC) patients (pts) with poly-ADP-ribose polymerase inhibitor (PARPi) resistance: A multi-institutional study.
- Ang, Joo Ern; Gourley, Charlie; High, Hilda Anne; Shapira-Frommer, Ronnie; Powell, C. Bethan; Castonguay, Vincent; De Greve, Jacques; Yap, Timothy Anthony; Fong, Peter C.C.; Olmos, David; Banerjee, Susana N.; Chen, Lee-may; Friedlander, Michael; Kaufman, Bella; Oza, Amit M.; De Bono, Johann Sebastian; Gore, Martin Eric; Kaye, Stanley B.; The Royal Marsden NHS Foundation Trust and The Institute of Cancer Research, Sutton, United Kingdom; Edinburgh Cancer Research Centre, MRC IGMM, University of Edinburgh, Western General Hospital, Edinburgh, United Kingdom; Prince of Wales Cancer Centre, Sydney, Australia; Chaim Sheba Medical Center, Tel Hashomer, Israel; University of California, San Francisco Comprehensive Cancer Center, San Francisco, CA; Princess Margaret Hospital, Toronto, ON, Canada; Oncologisch Centrum UZ Brussel, Brussels, Belgium; The Royal Marsden NHS Foundation Trust and The Institute of Cancer Research, Sutton, United Kingdom; The Royal Marsden NHS Foundation Trust and The Institute of Cancer Research, Sutton, United Kingdom; The Royal Marsden NHS Foundation Trust and The Institute of Cancer Research, Sutton, United Kingdom; The Royal Marsden NHS Foundation Trust and The Institute of Cancer Research, Sutton, United Kingdom; University of California, San Francisco Comprehensive Cancer Center, San F; (Journal of clinical oncology : official journal of the American Society of Clinical Oncology, v.30, 2012, pp.5022-5022)
-
69
- Evaluation of a Series of Naphthamides as Potent, Orally Active Vascular Endothelial Growth Factor Receptor-2 Tyrosine Kinase Inhibitors
- Weiss, Matthew M.; Harmange, Jean-Christophe; Polverino, Anthony J.; Bauer, David; Berry, Loren; Berry, Virginia; Borg, George; Bready, James; Chen, Danlin; Choquette, Deborah; Coxon, Angela; DeMelfi, Tom; Doerr, Nicholas; Estrada, Juan; Flynn, Julie; Graceffa, Russell F.; Harriman, Shawn P.; Kaufman, Stephen; La, Daniel S.; Long, Alexander; Neervannan, Sesha; Patel, Vinod F.; Potashman, Michele; Regal, Kelly; Roveto, Phillip M.; Schrag, Michael L.; Starnes, Charlie; Tasker, Andrew; Teffera, Yohannes; Whittington, Douglas A.; Zanon, Roger; ; (Journal of medicinal chemistry, v.51, 2008, pp.1668-1680)
-
70
- Efficacy of Chemotherapy in <i>BRCA1/2</i> Mutation Carrier Ovarian Cancer in the Setting of PARP Inhibitor Resistance: A Multi-Institutional Study
- Ang, Joo Ern; Gourley, Charlie; Powell, C. Bethan; High, Hilda; Shapira-Frommer, Ronnie; Castonguay, Vincent; De Greve, Jacques; Atkinson, Tina; Yap, Timothy A.; Sandhu, Shahneen; Banerjee, Susana; Chen, Lee-May; Friedlander, Michael L.; Kaufman, Bella; Oza, Amit M.; Matulonis, Ursula; Barber, Louise J.; Kozarewa, Iwanka; Fenwick, Kerry; Assiotis, Ioannis; Campbell, James; Chen, Lina; de Bono, Johann S.; Gore, Martin E.; Lord, Christopher J.; Ashworth, Alan; Kaye, Stan B.; Authors' Affiliations: The Royal Marsden NHS Foundation Trust and The Institute of Cancer Research, Sutton; Edinburgh Cancer Research UK Center, Medical Research Council Institute of Genetics and Molecular Medicine, University of Edinburgh, Western General Hospital, Edinburgh; The Cancer Research UK Gene Function Laboratory; Breakthrough Breast Cancer Research Center; Tumour Profiling Unit, The Institute of Cancer Research, London, United Kingdom; University of California San Francisco, San Francisco, California; Department of Medical Oncology, Prince of Wales Clinical School, Prince of Wales Hospital, Sydney, Australia; The Chaim Sheba Medical Center, Tel Hashomer, Israel; Princess Margaret Hospital, Toronto, Canada; Oncologisch Centrum Vrije Universiteit Brussel, Brussels, Belgium; and Dana Farber Cancer Center, Boston, Massachusetts; Authors' Affiliations: The Royal Marsden NHS Foundation Trust and The Institute of Cancer Research, Sutton; Edinburgh Cancer Research UK; (Clinical Cancer research : an official journal of the American Association for Cancer Research, v.19, 2013, pp.5485-5493)
QUICK MENU
